SAN DIEGO and SUZHOU, China, Aug. 26, 2025 — Adagene Inc. (Nasdaq: ADAG), a company focused on innovative antibody-based therapies, announced today that its Chief Strategy Officer, Mickael Chane-Du, will attend investor meetings and participate in a fireside chat at two investor conferences in New York City this September.

H.C. Wainwright 27th Annual Global Investment Conference

  • Fireside Chat Date: Monday, September 8
  • Fireside Chat Time: 11:00 AM (Eastern Time)
  • Location: Lotte New York Palace Hotel
  • Webcast:

Morgan Stanley 23rd Annual Global Healthcare Conference

  • Fireside Chat Date: Wednesday, September 10
  • Fireside Chat Time: 7:00 AM (Eastern Time)
  • Location: Sheraton New York Times Square Hotel
  • Webcast:

A webcast of the presentations will be available in the section of the company’s website at for a minimum of 30 days.

About Adagene
Adagene Inc. (Nasdaq: ADAG) is a clinical-stage biotechnology company that utilizes a platform-driven approach to discover and develop innovative antibody-based cancer immunotherapies. Adagene employs computational biology and artificial intelligence to create novel antibodies that address unmet global patient needs. The company has established strategic collaborations with respected global partners, leveraging its SAFEbody® precision masking technology in various cutting-edge scientific approaches.

Fueled by its proprietary Dynamic Precision Library (DPL) platform, which includes NEObody™, SAFEbody, and POWERbody™ technologies, Adagene’s pipeline boasts novel immunotherapy programs. The company’s SAFEbody technology is designed to improve the safety and tolerability of antibody therapeutics by using precision masking to shield the biologic therapy’s binding domain. Activation within the tumor microenvironment allows for tumor-specific targeting of antibodies, minimizing off-target toxicity in healthy tissues.

Adagene’s leading clinical program, ADG126 (muzastotug), is a masked, anti-CTLA-4 SAFEbody targeting a specific CTLA-4 epitope in regulatory T cells (Tregs) within the tumor microenvironment. ADG126 is currently undergoing phase 1b/2 clinical trials in combination with anti-PD-1 therapy, with a focus on Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC). The SAFEbody platform, validated by ongoing clinical research, can be applied to various antibody-based therapeutic modalities, including Fc empowered antibodies, antibody-drug conjugates, and bi/multi-specific T-cell engagers.

For more information, please visit: .

Follow Adagene on , and .

SAFEbody® is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union.

Investor Contacts:

Raymond Tam

Corey Davis
LifeSci Advisors

“`